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Introduc)on
Background:  Nanoparticles have been an area of active research 
for several decades due to their interesting physical and chemical 
properties2.   They have  found widespread  use  in  several  sectors 
such  as  chemical  sensing,  imaging,  and  photovoltaics1.   One 
important  application  is  their  potential  use  as  drug  delivery 
vehicles2.  Surface  modifications  have  been  shown  to  allow  for 
targeted  binding  with  specific  cell  types  that  increases  the 
therapeutic  dose  at  the  site  of  interest4.  The  ability  to  tailor  the 
shape and core composition of  nanoparticles  affords a  wealth of 
possible  combinations  for  investigation.  Nanoparticles 
functionalized  separately  with  luminol,  with  lipids,  and 
poly(allylamine  hydrochloride)  (PAH)  have  been  found  to  have 
many advantages such as detection through Raman spectroscopy, 
immune system evasion, and increased stability, respectively3,5.
Goals:  In  this  research,  nanoparticles  are  being  layered  with  all 
three  components  to  capitalize  on  each  of  these  benefits.  An 
important goal of nanoparticle synthesis is to achieve particles that 
are monodisperse in size. This is often difficult to achieve due to 
their tendency to aggregate, resulting in a relatively small number 
of nanoparticles of useable size.  Moreover, aggregation can lead to 
difficulties  in  analytical  determinations  of  successful  surface 
modifications.  Results  herein  suggest  that  monodispersity  was 
successfully  maintained  for  both  metal  nanoparticles  after 
functionalization with PAH and lipids. 
Materials	and	Methods
Citrate Capped Nanoparticle Synthesis 
v  Sodium tri-citrate (1.0-2.5 mL, 1%) was mixed with chloroauric 
acid (1.5 mL, 0.01 mM) and DI H20 (50 mL) upon boiling and 
was refluxed for 30 min. 
v  Silver nitrate (25 mL, 1 mM) was mixed with DI H20 (25ml) 
followed by sodium tri-citrate (2.5 mL, 1%) upon boiling and 
was refluxed for 30 min. 
v  Each  separate  mixture  was  cooled  on  ice  to  generate  gold 
nanoparticles (AuNPs) and silver nanoparticles (AgNPs). 
 
Poly(allylamine hydrochloride) (PAH) coating
v  Sample  aliquots  (1.0  mL)  were  centrifuged  and  the  pellets 
collected and resuspended (1.0 mL DI H20 each).  
v  Particles  were  stored  overnight  at  room  temperature  after 
addition of 100 µL sodium chloride (0.1 M) and 200 µL PAH 
(10 mg/mL).
 
Lipid Coating
v  PAH  coated  nanoparticle  aliquots  were  centrifuged  and  the 
pellets resuspended in HEPES (0.5 mL, 20 mM, pH 7.19). 
v  A  1:1  weight  ratio  of  1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-L-serine  (POPS)  and  lysophosphatidylcholine  (LPC) 
solution (0.5 mL) was added to each 0.5 mL PAH coated sample 
and allowed to incubate overnight.  
v  Lipid-coated  samples  were  centrifuged  and  the  pellet  was 
resuspended in HEPES buffer (1 mL, 20 mM).
 
Sample Analysis
v  Samples were analyzed after coating and purification through a 
Shimadzu 2600 UV-vis spectrophotometer, a Malvern LM10 HS 
NanoSight particle sizer, and will be analyzed through Raman 
spectroscopy after coating and purification with luminol. 
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Figure 1. Distribution of diameter sizes (nm) in a gold nanoparticle sample made from 
1.00 mL tri-sodium citrate after each surface modification.  
 
 
 
 
 
 
 
 
 
 
          
Figure 2. Extinction spectra after each gold nanoparticle (generated from 1.00 mL tri-
sodium citrate) surface modification. 
    
    
 
 
 
 
 
 
 
 
 
 
Figure 3.  Distribution of diameter sizes (nm) in a silver nanoparticle sample made 
from 2.50 mL tri-sodium citrate after each surface modification.  
 
 
 
 
 
 
Figure 4. Extinction spectra after each silver nanoparticle (generated from 2.50 mL tri-
sodium citrate) surface modification. 
               
Discussion	
Size Results:  In general,  size increases were detected upon each 
additional surface modification. Relative monodispersity was also 
maintained  with  each  successive  modification.  Both  nanoparticle 
solutions  underwent  approximately  60  nm  increase  in  mean 
diameter upon functionalization with lipids.
Optical  Results:  Both  solutions  underwent  an  approximately  11 
nm  red  shift  upon  functionalization  with  lipids,  and  maximum 
extinction  was  typically  observed  to  increase  with  each 
modification, suggesting successful coating. 
Conclusion
v  The  data  collected  suggests  the  successful  synthesis  and 
modification  of  gold  and  silver  nanoparticles  with  LPC  and 
POPS lipids. 
v  This work is significant because it demonstrates that a variety of 
different  nanoparticles  consisting  of  different  cores  can  be 
functionalized and could potentially be further functionalized for 
use as drug delivery vehicles. 
Future	Work
v Further  functionalization  with  luminol,  a  Surface  Enhanced 
Raman Scattering tag molecule, will be investigated next. 
v If monodispersity with luminol is maintained, the particles will 
be introduced into cell cultures to monitor for cellular uptake. 
v Lipid coated gold-silver alloy nanoparticles will be investigated 
as well, since current efforts have maintained monodispersity up 
until PAH coating. 
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